Raynaud's Treatment Study (RTS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00000530|
Recruitment Status : Completed
First Posted : October 28, 1999
Last Update Posted : April 15, 2016
|Condition or disease||Intervention/treatment||Phase|
|Cardiovascular Diseases Heart Diseases Raynaud's Disease Vascular Diseases||Drug: nifedipine Behavioral: biofeedback (psychology) Procedure: electromyography||Phase 3|
Primary Raynaud's phenomenon is a peripheral vascular disorder resulting in vasospastic attacks provoked by cold and/or emotional stress. Attacks most often occur in the fingers, but may occur in other extremities as well.
Randomized. Patients were assigned to one of four treatment groups: slow release Nifedipine, a calcium channel blocker; pill placebo; temperature biofeedback; or electromyograph biofeedback from the frontalis muscle. The primary endpoint was reduction in number of vasospastic attacks. Other endpoints included: other measures of Raynaud's attacks including frequency, severity, duration, response to laboratory-based cold challenge, and quality of life.
|Study Type :||Interventional (Clinical Trial)|
|Study Start Date :||September 1992|
|Study Completion Date :||June 1998|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000530
|OverallOfficial:||Bruce Thompson||Clinical Trials & Surveys Corp (C-TASC)|